New Clinical Results for ONPATTRO® (patisiran) at 2019 PNS Annual Meeting

24 Jun, 2019 New Clinical Results for ONPATTRO® (patisiran) at 2019 PNS Annual Meeting

We presented new 12-month interim results from the ongoing Global Open-Label Extension (OLE) study of ONPATTRO^® (patisiran), demonstrating maintained reversal of disease progression and consistent safety profile with >4 years of patient experience and >6,000 doses administered. These results were presented at the 2019 Peripheral Nerve Society (PNS) Annual Meeting, held June 22-26 in Genoa, Italy.

Read our press release

Polydefkis et al. – “Long-Term Safety and Efficacy of Patisiran in Patients with hATTR Amyloidosis: Global OLE Study”

Lin et al. – “Efficacy of Patisiran in Patients with hATTR Amyloidosis and Prior Tafamidis Use: Analysis of APOLLO”

Obici et al. – “Indirect Treatment Comparison of the Efficacy of Patisiran and Inotersen for hATTR Amyloidosis with Polyneuropathy”

We also presented results demonstrating that APOLLO patients previously on tafamidis benefitted from patisiran, with improvements in neuropathy impairment and quality of life.

Additionally, indirect treatment comparison results show favorable treatment effects of patisiran relative to inotersen across all endpoints assessed in an evaluation of efficacy from the APOLLO and NEURO-TTR Phase 3 studies, respectively.